Adherence to guidelines for androgen deprivation therapy after radical prostatectomy: Swedish population-based study

References

• Van den Bergh RCN, van Casteren NJ, van den Broeck T, et al. Role of hormonal treatment in prostate cancer patients with nonmetastatic disease recurrence after local curative treatment: a systematic review. Eur Urol. 2016;69:802–820.
   PubMed Web of Science ®Google Scholar
• Moul JW, Wu H, Sun L, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2004;171:1141–1147.
   PubMed Web of Science ®Google Scholar
• Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591–1597.
   PubMed Web of Science ®Google Scholar
• Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer–specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433–439.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Feng Z, Trock BJ, et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int. 2012;109:32–39.
   PubMed Web of Science ®Google Scholar
• Brockman JA, Alanee S, Vickers AJ, et al. Nomogram predicting prostate cancer–specific mortality for men with biochemical recurrence after radical prostatectomy. Eur Urol. 2015;67:1160–1167.
   PubMed Web of Science ®Google Scholar
• Boorjian SA, Thompson RH, Tollefson MK, et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol. 2011;59:893–899.
   PubMed Web of Science ®Google Scholar
• D’Amico AV, Moul J, Carroll PR, et al. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol. 2004;172:42–47.
   PubMedGoogle Scholar
• Nguyen PL, Alibhai SMH, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67:825–836.
   PubMed Web of Science ®Google Scholar
• Thorstenson A, Bratt O, Akre O, et al. Incidence of fractures causing hospitalisation in prostate cancer patients: results from the population-based PCBaSe Sweden. Eur J Cancer. 2012;48:1672–1681.
   PubMed Web of Science ®Google Scholar
• Crawley D, Garmo H, Rudman S, et al. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer. Int J Cancer. 2016;139:2698–2704.
   PubMed Web of Science ®Google Scholar
• O'Farrell S, Garmo H, Holmberg L, et al. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2015;33:1243–1251.
   PubMed Web of Science ®Google Scholar
• O'Farrell S, Sandström K, Garmo H, et al. Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy. BJU Int. 2016;118:391–398.
   PubMed Web of Science ®Google Scholar
• Donovan KA, Walker LM, Wassersug RJ, et al. Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners. Cancer. 2015;121:4286–4299.
   PubMed Web of Science ®Google Scholar
• European Association of Urology. Prostate Cancer. [accessed 2020 Jan 5]. Available from: https://uroweb.org/guideline/prostate-cancer/#6_3
   Google Scholar
• Lycken M, Garmo H, Adolfsson J, et al. Patterns of androgen deprivation therapies among men diagnosed with localised prostate cancer: a population-based study. Eur J Cancer. 2014;50:1789–1798.
   PubMed Web of Science ®Google Scholar
• The National Prostate Cancer Register of Sweden. English. [accessed 2020 Jan 5]. Available from: http://npcr.se/in-english/
   Google Scholar
• Van Hemelrijck M, Garmo H, Wigertz A, et al. Cohort profile update: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base—a refined prostate cancer trajectory. Int J Epidemiol. 2016;45:73–82.
   PubMed Web of Science ®Google Scholar
• Regionala cancercentrum i samverkan. Vårdprogram. [accessed 2020 Jan 5]. Available from: https://www.cancercentrum.se/samverkan/cancerdiagnoser/prostata/vardprogram/
   Google Scholar
• Kastner C, Armitage J, Kimble A, et al. The Charlson comorbidity score: a superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting. Prostate Cancer Prostatic Dis. 2006;9:270–274.
   PubMed Web of Science ®Google Scholar
• Francke AL, Smit MC, de Veer AJ, et al. Factors influencing the implementation of clinical guidelines for health care professionals: a systematic meta-review. BMC Med Inform Decis Mak. 2008;8:38.
   PubMed Web of Science ®Google Scholar
• Shahinian VB, Kuo YF, Freeman JL, et al. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst. 2006;98:839–845.
   PubMed Web of Science ®Google Scholar
• Cabana MD, Rand CS, Powe NR, et al. Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282:1458–1465.
   PubMed Web of Science ®Google Scholar
• Dale W, Hemmerich J, Bylow K, et al. Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: a prospective cohort study. J Clin Oncol. 2009;27:1557–1563.
   PubMed Web of Science ®Google Scholar
• Mahal BA, Chen MH, Bennett CL, et al. High PSA anxiety and low health literacy skills: drivers of early use of salvage ADT among men with biochemically recurrent prostate cancer after radiotherapy? Ann Oncol. 2015;26:1390–1395.
   PubMed Web of Science ®Google Scholar
• Flodgren G, Hall AM, Goulding L, et al. Tools developed and disseminated by guideline producers to promote the uptake of their guidelines. Cochrane Database Syst Rev. 2016:CD010669.
   PubMed Web of Science ®Google Scholar
• Baker R, Camosso-Stefinovic J, Gillies C, et al. Tailored interventions to overcome identified barriers to change: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2010:CD005470.
   PubMed Web of Science ®Google Scholar
• Arts DL, Voncken AG, Medlock S, et al. Reasons for intentional guideline non-adherence: a systematic review. Int J Med Inf. 2016;89:55–62.
   PubMed Web of Science ®Google Scholar
• Kunath F, Grobe HR, Rücker G, et al. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer. Cochrane Database Syst Rev. 2014:CD009266.
   PubMed Web of Science ®Google Scholar
• Iversen P, Tyrrell CJ, Kaisary AV, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol. 2000;164:1579–1582.
   PubMed Web of Science ®Google Scholar
• Mcleod DG, Iversen P, See WA, et al.; the Casodex Early Prostate Cancer Trialists’ GroupP. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int. 2006;97:247–254.
   PubMed Web of Science ®Google Scholar